Brief: Medicenna Announces Clinical Collaboration With Merck To Evaluate MDNA11 In Combination With Keytruda® (Pembrolizumab) In Ability Trial
13/09/2022 12:10
Sept 13 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA ANNOUNCES CLINICAL COLLABORATION WITH MERCK TO
EVALUATE MDNA11 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN
ABILITY TRIAL
* MEDICENNA THERAPEUTICS - UNDER TERMS OF CLINICAL TRIAL
SUPPLY
AND COLLABORATION AGREEMENT, MEDICENNA WILL SPONSOR STUDY AND
MERCK WILL SUPPLY KEYTRUDA
Source text for Eikon: ID:nGNX98j5Y0
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results